Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.86 |
| ▸ | BRD4 | O60885 | 18/20 | 0.86 |
| ▸ | BRDT | Q58F21 | 15/20 | 0.86 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.70 |
| ▸ | CLK2 | P49760 | 3/20 | 0.70 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.70 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.70 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.70 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.70 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.70 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.70 |
| ▸ | PRKCG | P05129 | 2/20 | 0.70 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.70 |
| ▸ | NEK4 | P51957 | 2/20 | 0.70 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.70 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.69 |
| ▸ | TAF1 | P21675 | 2/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31098113 | 1.00 | PLK1 (0.86) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL862080 | 0.99 | PLK1 (0.85) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL25787913 | 0.91 | PLK1 (0.85) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL3673712 | 0.91 | PLK1 (0.72) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL21527106 | 0.90 | PLK1 (0.70) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL861945 | 0.90 | PLK1 (0.70) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL15257514 | 0.90 | PLK1 (0.87) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL10098781 | 0.89 | PLK1 (0.69) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL618641 | 0.89 | PLK1 (0.69) | PLK1BRD4BRDTPLK3PRKD3 | |
| SCHEMBL376134 | 0.89 | PLK1 (0.87) | PLK1BRD4BRDTPLK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2275107-B1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INT (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-8143247-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143247-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| EP-2409706-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-8058270-B2 | Dihydropteridinones for the treatment of cancer diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| EP-1599478-B1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | PLK4, TK1, POLK | PLK1 6/4885BRD4 4296/4885BRDT 2760/4885 |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | PLK1 162/4885BRD4 2468/4885BRDT 760/4885 |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | PLK1 162/4885BRD4 2468/4885BRDT 760/4885 |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | PLK1 2334/4885BRD4 4860/4885BRDT 4719/4885 |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | QDPR, DHPS, DHODH | PLK1 4090/4885BRD4 4628/4885BRDT 4504/4885 |
| US-20080293944-A1 | Piperazinyl Compounds | QDPR, DHPS, DPYD | PLK1 3628/4885BRD4 4157/4885BRDT 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.